NCT02680808View on ClinicalTrials.gov

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Invasive Aspergillosis

Interventions

DRUG

Midazolam with F901318

Pharmacokinetics of midazolam with F901318

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

F2G Biotech GmbH

All Listed Sponsors

collaborator

Hammersmith Medicines Research

OTHER

lead

F2G Biotech GmbH

INDUSTRY

NCT02680808 - Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe | Biotech Hunter | Biotech Hunter